Literature DB >> 12960682

Beneficial effect of sodium nitroprusside after coronary artery bypass surgery: pump function correlates inversely with cardiac release of proinflammatory cytokines.

Tobias Freyholdt1, Parwis Massoudy, Stefan Zahler, Richard Henze, Andreas Barankay, Bernhard F Becker, Hans Meisner.   

Abstract

The authors studied the relationship between cardiac cytokine release and pump function and whether low-dose application of sodium nitroprusside (SNP) improves cardiac performance during coronary artery bypass graft (CABG) creation. Cardiac reperfusion and application of nitric oxide have an influence on cytokine release. However, the functional consequences are unclear. Patients with CABGs (n = 30) with severely compromised left ventricular ejection fraction (<40%) were treated with either SNP (0.5 microg/kg/min) or placebo for the first 60 minutes of reperfusion after cardiac arrest. Interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-alpha were determined in blood samples from the radial artery and coronary sinus during reperfusion (5, 35, and 75 minutes). Hemodynamic measurements were performed before and after cardiopulmonary bypass and at the end of surgery. In all patients, the cardiac index at the end of surgery correlated negatively with levels of TNF-alpha at 5 minutes (r = 0.398; P < 0.05), IL-8 at 35 minutes (r = 0.394; P < 0.05), and IL-6 at 75 minutes of reperfusion (r = 0.421; P < 0.025). Sodium nitroprusside improved the cardiac index immediately after reperfusion (4.4 L/min/m2 +/- 0.3 vs. 3.7 L/min/m2 +/- 0.1; P = 0.014) and at the end of surgery (3.8 L/min/m2 +/- 0.3 vs. 3.0 L/min/m2 +/- 0.2; P = 0.023). The negative correlation between cardiac index and transcardiac cytokines suggests that reducing cardiac inflammatory reaction improves postischemic cardiac function. This was achieved by treating CABG patients with the nitric oxide donor SNP at a dosage without vasodilatory action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960682     DOI: 10.1097/00005344-200309000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics.

Authors:  M-S Suleiman; K Zacharowski; G D Angelini
Journal:  Br J Pharmacol       Date:  2007-10-22       Impact factor: 8.739

2.  Examining the Use of Sodium Nitroprusside in Coronary Artery Bypass Grafting: Is the Benefit Worth the Cost?

Authors:  Caitlin M Gibson; Sondra Davis; Darien Bradford
Journal:  Hosp Pharm       Date:  2017-07-30

Review 3.  Cardioplegic strategies to protect the hypertrophic heart during cardiac surgery.

Authors:  M-S Suleiman; M Hancock; R Shukla; C Rajakaruna; G D Angelini
Journal:  Perfusion       Date:  2011-09       Impact factor: 1.972

4.  The Effects of Levosimendan and Sodium Nitroprusside Combination on Left Ventricular Functions After Surgical Ventricular Reconstruction in Coronary Artery Bypass Grafting Patients.

Authors:  Zeki Temizturk; Davut Azboy; Atakan Atalay; Hakan Atalay; Omer Faruk Dogan
Journal:  Open Cardiovasc Med J       Date:  2016-06-30

5.  Cardioprotective effect of ghrelin in cardiopulmonary bypass involves a reduction in inflammatory response.

Authors:  Yukun Cao; Jun Tang; Ting Yang; Heng Ma; Dinghua Yi; Chunhu Gu; Shiqiang Yu
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

Review 6.  Nitric oxide donors as neuroprotective agents after an ischemic stroke-related inflammatory reaction.

Authors:  Marisol Godínez-Rubí; Argelia E Rojas-Mayorquín; Daniel Ortuño-Sahagún
Journal:  Oxid Med Cell Longev       Date:  2013-04-04       Impact factor: 6.543

7.  Exogenous nitric oxide requires an endothelial glycocalyx to prevent postischemic coronary vascular leak in guinea pig hearts.

Authors:  Dirk Bruegger; Markus Rehm; Matthias Jacob; Daniel Chappell; Mechthild Stoeckelhuber; Ulrich Welsch; Peter Conzen; Bernhard F Becker
Journal:  Crit Care       Date:  2008-06-02       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.